Almitas Capital LLC Cuts Stake in Rallybio Corporation $RLYB

Key Points

• Almitas Capital cut its Rallybio stake by 36.9% in the second quarter, selling 70,524 shares and retaining 120,682 shares worth approximately $1.93 million.
• Other institutional investors made significant purchases, including ADAR1 Capital Management, which increased its position by more than 4,400%; hedge funds and institutions collectively own 90.34% of Rallybio.
• Rallybio shares opened at $16.76, near their 52-week high, while analysts maintain an average “Hold” rating. The company reported a quarterly loss of $1.09 per share, better than the consensus estimate of a $1.28 loss.

Almitas Capital LLC lowered its stake in shares of Rallybio Corporation (NASDAQ:RLYB - Free Report) by 36.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,682 shares of the company's stock after selling 70,524 shares during the period. Almitas Capital LLC owned 2.27% of Rallybio worth $1,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. ADAR1 Capital Management LLC boosted its holdings in shares of Rallybio by 4,411.1% during the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company's stock valued at $14,822,000 after purchasing an additional 905,817 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after buying an additional 2,996 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after buying an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its stake in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, Citadel Advisors LLC boosted its stake in Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RLYB. Weiss Ratings raised Rallybio from a "sell (d-)" rating to a "hold (c-)" rating in a report on Wednesday, August 19th. Wall Street Zen upgraded shares of Rallybio from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Hold".

Rallybio Price Performance

Shares of RLYB stock opened at $16.76 on Friday. The company has a market cap of $89.01 million, a PE ratio of -3.86 and a beta of -0.90. Rallybio Corporation has a 1 year low of $3.67 and a 1 year high of $17.57. The stock's 50 day simple moving average is $16.25 and its two-hundred day simple moving average is $12.60.

Rallybio (NASDAQ:RLYB - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Rallybio Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.